2 files

The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease.

posted on 18.11.2019, 11:12 authored by Joshua J Solomon, Sonye K Danoff, Hilary J Goldberg, Felix Woodhead, Martin Kolb, Daniel C Chambers, Donna DiFranco, Cathy Spino, Shana Haynes-Harp, Shelley Hurwitz, Elizabeth B Peters, Paul F Dellaripa, Ivan O Rosas, on behalf of the Trail Network

Provide enhanced digital features for this article

If you are an author of this publication and would like to provide additional enhanced digital features for your article then please contact adisrapidplus@springer.com.

The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.

Other enhanced features include, but are not limited to:
• Slide decks
• Videos and animations
• Audio abstracts
• Audio slides


Genentech, a member of the Roche Group.